Author | Lightnews

Society of Hematologic Oncology @societyofhemonc.bsky.social · 24m

SOHO pilot program finds structured learning improves practice in R/R CLL/SLL

sohoinsider.com/news/soho-pi...

SOHO pilot program finds structured learning improves practice in R/R CLL/SLL - SOHO Insider

At the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), a new pilot program debuted to educate and empower the next generation of clinicians treating patients with relapse...

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 1d

ICYMI: Daratumumab, bortezomib, lenalidomide, dexamethasone combo shows efficacy in myeloma across risk groups.

Daratumumab, bortezomib, lenalidomide, dexamethasone combo shows efficacy in myeloma across risk groups

By: Kerri Fitzgerald A study presented by Saad Usmani, MD, MBA, of the Memorial Sloan Kettering Cancer Center, as part of the SOHO 2025 Annual Meeting, showed that the combination of daratumumab,…

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 2d

"People may think physicians become hardened, but the longer you do this, the more you understand what lies ahead for your patients" Gabriela Hobbs said in our Pathways & Perspectives! @massgeneralbrigham.bsky.social

sohoinsider.com/news/pathway...

Pathways & Perspectives with Gabriela Hobbs, MD - SOHO Insider

Dr. Hobbs, MPN lead and clinical director for the Adult Leukemia Service at Massachusetts General Hospital, was born in Mexico City, came to the US for college and her medical training.

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 5d

FDA approves revumenib in relapsed or refractory NMP1-mutated #AML

sohoinsider.com/leukemia/fda...

FDA approves revumenib in relapsed NMP1-mutated AML

FDA approves revumenib in relapsed or refractory NMP1-mutated AML. Syndax announced the approval in a press release.

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 6d

FDA approves blenrep combo in relapsed or refractory MM

sohoinsider.com/multiple-mye...

FDA approves blenrep combo in relapsed or refractory MM - SOHO Insider

The US Food and Drug Administration (FDA) has approved belantamab mafodotin-blmf; blenrep) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or r...

sohoinsider.com

1

Society of Hematologic Oncology @societyofhemonc.bsky.social · 7d

FDA grants orphan drug designation to MDS investigational therapy ofirnoflast

sohoinsider.com/news/fda-gra...

FDA has granted orphan drug designation to ofirnoflast

The FDA has granted orphan drug designation to ofirnoflast (HT-6184), an investigational therapy for myelodysplastic symptoms (MDS).

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 7d

Despite digital advances, cancer research remains costly, burdensome
sohoinsider.com/leukemia/acu...

Despite digital advances, cancer research remains costly

Clinical cancer research remains too expensive and too burdensome, even amid a proliferation of digital tools designed to improve it, according to Ines Vaz-Luis, MD, PhD, who spoke at the 2025 Europea...

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 7d

SOHO MENA returns to in-person meeting for region’s 3rd meeting
sohoinsider.com/myelodysplas...

SOHO MENA returns to in-person meeting for region’s 3rd meeting

SOHO MENA was held Sept. 25–27 in Beirut and marked a return to in-person collaboration after the meeting was held virtually the prior year.

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 9d

Watch @NicholasShortMD with @DrHKantarjian at #SOHO2025 on the future of CAR-T in #ALL.

"I think the future... will be CAR-T cell consolidation...particularly for high-risk patients who otherwise might be referred for stem cell transplant."

Watch now: buff.ly/qvfnjX7

Society of Hematologic Oncology @societyofhemonc.bsky.social · 9d

ICYMI: VERONA phase 3 trial shows no survival benefit in high-risk MDS

sohoinsider.com/news/verona-...

VERONA phase 3 trial shows no survival benefit in high-risk MDS - SOHO Insider

The study, presented by Guillermo Garcia-Manero, MD, interim chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, evaluated the efficacy and safety of venetoclax i...

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 13d

This Meet-the-Professor session with Uma Borate, MD, MS,
brought expert insight to #SOHO2025

sohoinsider.com/news/improvi...

Improving Outcomes in CHIP/CCUS with Dr. Borate - SOHO Insider

This Meet-the-Professor session was delivered by Uma Borate, MD, MS, at SOHO 2025 in Houston, Texas, in September 2025.

sohoinsider.com

1

Society of Hematologic Oncology @societyofhemonc.bsky.social · 13d

ICYMI: FDA grants orphan drug designation for AK117 (ligufalimab)

FDA grants Orphan Drug Designation for AK117 (ligufalimab)

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to AK117 (ligufalimab) for the treatment of acute myeloid leukemia (AML). Ligufalimab is a humanized IgG4 monoclonal…

buff.ly

Society of Hematologic Oncology @societyofhemonc.bsky.social · 14d

"By doing these studies, all of us have learned how to manage and utilize #CAR-T cells better," says Aaron Logan, Elias Jabbour, & Ibrahim Aldoss on managing #CAR-T and transplant in treatment.

sohoinsider.com/news/drs-jab...

Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL

In this panel discussion at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Elias Jabbour, MD, leukemia professor at the University of Texas MD Anderson Cancer…

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 15d

Enasidenib plus venetoclax shows activity in relapsed or refractory IDH2-mutated AML
sohoinsider.com/leukemia/ena...

Society of Hematologic Oncology @societyofhemonc.bsky.social · 15d

Outside of clinical trials, available data with the second-generation TKI dasatinib show very strong results, says Dr. Nicholas Short in this interview with Dr Kantarjian at #SOHO2025.

sohoinsider.com/news/drs-kan...

Society of Hematologic Oncology @societyofhemonc.bsky.social · 17d

ICYMI: Phase 3 CEPHEUS study shows 'strong efficacy' of quadruplet therapy for transplant-ineligible myeloma.

Phase 3 CEPHEUS study shows “strong efficacy” of quadruplet therapy for transplant-ineligible myeloma

By: Kerri Fitzgerald The addition of daratumumab to bortezomib, lenalidomide, and dexamethasone (D-VRd) improved outcomes in patients with newly diagnosed multiple myeloma (MM) compared with VRd…

sohoinsider.com

1

Society of Hematologic Oncology @societyofhemonc.bsky.social · 19d

How to muddle through the less good times? Practice aequanimitas
sohoinsider.com/news/practic...

How to muddle through the less good times? Practice aequanimitas - SOHO Insider

I do search for and draw on messages that speak to me to muddle through the less good times. One is a mantra instilled in me since I was an intern: Aequanimitas

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 22d

BTK ‘degrader’ bexdeg shines in Waldenström macroglobulinemia
sohoinsider.com/news/btk-deg...

Bexobrutideg shows promise in WM at SOHO 2025 - SOHO Insider

SOHO 2025 data on bexobrutideg reveal strong efficacy and safety in relapsed WM, advancing blood cancer treatment.

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 26d

BTK ‘degrader’ bexdeg shines in Waldenström macroglobulinemia
ICYMI:

BTK ‘degrader’ bexdeg shines in Waldenström macroglobulinemia

By: Emily Hayes Attendees of SOHO 2025 got a closer look at positive early safety and efficacy data for the novel Bruton’s tyrosine kinase (BTK)-targeted drug bexobrutideg in heavily pretreated…

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 27d

Early-phase CLL trial shows bexobrutideg well tolerated
sohoinsider.com/meetings-con...

Early-phase CLL trial shows bexobrutideg well tolerated

Updated results from an early-phase CLL trial of heavily pretreated patients showed that the BTK inhibitor bexobrutideg was well tolerated.

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 27d

Radiation from medical imaging increases risk of blood cancers in children

buff.ly/OgNysqI

Society of Hematologic Oncology @societyofhemonc.bsky.social · 27d

SOHO 2026 exhibit & sponsorship opportunities are open! Connect with 3,000+ HemOnc professionals, maximize visibility, and build lasting connections. Space is limited and first-come, first-served—secure your spot today at soho.click/sponsors

#SOHO2026

Society of Hematologic Oncology @societyofhemonc.bsky.social · 28d

BLA submitted to FDA for pivekimab sunirine in BPDCN
sohoinsider.com/leukemia/bla...

BLA submitted to FDA for pivekimab sunirine in BPDCN

A new BLA has been submitted to the US FDA for approval of the investigational therapy pivekimab sunirine for treatment of BPDCN.

sohoinsider.com

Society of Hematologic Oncology @societyofhemonc.bsky.social · 29d

Dr. Kantarjian interviews Dr. Graff on MorningSun trial at #SOHO2025

sohoinsider.com/meetings-con...

Reposted by Society of Hematologic Oncology

Society of Hematologic Oncology @societyofhemonc.bsky.social · Sep 25

The next breakthrough starts here 🔨. Join us on November 20 for a one-day, virtual meeting, featuring leaders in #hemonc. Save your seat by registering today at soho.click/SBBC. Free for members; $50 for non-SOHO members.

1